DM3-SMe

• Description:

  DM3-SMe is a maytansine derivative and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM3-SMe shows highly cytotoxic activity in vitro with an IC50 of 0.0011 nM[1][2].

• UNSPSC:

  12352203

• Target:

  ADC Payload; Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dm3-sme.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@]12[C@H]([C@@H]([C@](O3)([H])C[C@]([C@](/C=C/C=C(C)/CC4=CC(N(C)C(C[C@]2([H])OC([C@H](C)N(C)C(CCC(C)SSC)=O)=O)=O)=C(C(OC)=C4)Cl)([H])OC)(NC3=O)O)C)O1

• Molecular Formula:

  C38H54ClN3O10S2

• Molecular Weight:

  812.43

• References & Citations:

  [1]Chen H, et al. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2017 Aug 1;22 (8) .|[2]Yuliang Zhaoet al. Biomedical Nanomaterials. 2016-‎Science.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  ADC Related

• Clinical Information:

  No Development Reported

• Isoform:

  Maytansinoids

• CAS Number:

  [796073-70-6]